A. L. Cohn, G. C. Shumaker, P. Khandelwal, D. A. Smith, M. A. Neubauer, N. Mehta, et al., “An Open-Label, SingleArm, Phase 2 Trial of Panitumumab plus FOLFIRI as Second-Line Therapy in Patients with Metastatic Colorectal Cancer,” Clinical Colorectal Cancer, Vol. 10, No. 3, 2011, pp. 171-177. doi:10.1016/j.clcc.2011.03.022

has been cited by the following article:

• TITLE: Targeting HIF-1α and HIF-2α to Overcome Treatment Resistance Mediated by Oncogenic KRAS in Colorectal Cancer

  AUTHORS: Eva Gupta, Napoleon Santos, Yanxia Liu, Pamela Havre, Nam H. Dang, Hendrik Luesch, Long H. Dang

  KEYWORDS: Colon Cancer; EGFR; KRAS; HIF-1α; HIF-2

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.6, August 1, 2013

  ABSTRACT: Epidermal growth factor receptor inhibitors have shown promise in the treatment of colorectal cancers. However, activating KRAS mutations cause primary resistance to these agents and contribute to cancer progression. Downstream signaling of oncogenic KRAS induces activation of HIF-1α and HIF-2α which in turn activate genes that promote cell proliferation, obstruct cell death, and induce angiogenesis and metabolic adaptation. We will discuss clinical trial results with EGFR inhibitors, mechanism of resistance mediated by oncogenic KRAS, and strategies under clinical development to overcome KRAS-mediated resistance.